185 related articles for article (PubMed ID: 31901438)
21. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
Front Immunol; 2021; 12():734646. PubMed ID: 34795663
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
24. Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.
Du P; Ye L; Yang Y; Jiang WG
Anticancer Res; 2014 Nov; 34(11):6515-20. PubMed ID: 25368253
[TBL] [Abstract][Full Text] [Related]
25. Activation of aryl hydrocarbon receptor promotes invasion of clear cell renal cell carcinoma and is associated with poor prognosis and cigarette smoke.
Ishida M; Mikami S; Shinojima T; Kosaka T; Mizuno R; Kikuchi E; Miyajima A; Okada Y; Oya M
Int J Cancer; 2015 Jul; 137(2):299-310. PubMed ID: 25523818
[TBL] [Abstract][Full Text] [Related]
26. EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients.
Sakaeda T; Okamura N; Gotoh A; Shirakawa T; Terao S; Morioka M; Tokui K; Tanaka H; Nakamura T; Yagi M; Nishimura Y; Yokoyama M; Okumura K
Pharm Res; 2005 Oct; 22(10):1757-61. PubMed ID: 16180134
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine kinase expression profile in clear cell renal cell carcinoma.
Behbahani TE; Thierse C; Baumann C; Holl D; Bastian PJ; von Ruecker A; Müller SC; Ellinger J; Hauser S
World J Urol; 2012 Aug; 30(4):559-65. PubMed ID: 21969129
[TBL] [Abstract][Full Text] [Related]
28. VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
Liu C; Liu L; Wang K; Li XF; Ge LY; Ma RZ; Fan YD; Li LC; Liu ZF; Qiu M; Hao YC; Shi ZF; Xia CY; Strååt K; Huang Y; Ma LL; Xu D
Oncogene; 2020 May; 39(21):4286-4298. PubMed ID: 32291411
[TBL] [Abstract][Full Text] [Related]
29. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
30. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.
Fritz HKM; Lindgren D; Ljungberg B; Axelson H; Dahlbäck B
Eur J Cancer; 2014 Jul; 50(10):1758-1765. PubMed ID: 24793999
[TBL] [Abstract][Full Text] [Related]
31. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
[TBL] [Abstract][Full Text] [Related]
32. Bioinformatics analysis of immune-related prognostic genes and immunotherapy in renal clear cell carcinoma.
Pan Z; Chang S; Chen S; Zhao D; Zou Z; Dai L; Hou Y; Zhang Q; Yang Y; Chen Z; Zhang W; Zhao Y
PLoS One; 2022; 17(11):e0272542. PubMed ID: 36417422
[TBL] [Abstract][Full Text] [Related]
33. Proliferating cell nuclear antigen and epidermal growth factor receptor (EGFr) status in renal cell carcinoma patients with polysomy of chromosome 7.
Amare Kadam PS; Varghese C; Bharde SH; Narasimhamoorthy NK; Desai S; Advani SH; Havaldar R; Kulkarni JN
Cancer Genet Cytogenet; 2001 Mar; 125(2):139-46. PubMed ID: 11369057
[TBL] [Abstract][Full Text] [Related]
34. Influence of gene expression on survival of clear cell renal cell carcinoma.
Berglund A; Amankwah EK; Kim YC; Spiess PE; Sexton WJ; Manley B; Park HY; Wang L; Chahoud J; Chakrabarti R; Yeo CD; Luu HN; Pietro GD; Parker A; Park JY
Cancer Med; 2020 Nov; 9(22):8662-8675. PubMed ID: 32986937
[TBL] [Abstract][Full Text] [Related]
35. Apelin and apelin receptor expression in renal cell carcinoma.
Tolkach Y; Ellinger J; Kremer A; Esser L; Müller SC; Stephan C; Jung K; Toma M; Kristiansen G; Hauser S
Br J Cancer; 2019 Mar; 120(6):633-639. PubMed ID: 30783205
[TBL] [Abstract][Full Text] [Related]
36. Identification of EGFR as a Novel Key Gene in Clear Cell Renal Cell Carcinoma (ccRCC) through Bioinformatics Analysis and Meta-Analysis.
Wang S; Yu ZH; Chai KQ
Biomed Res Int; 2019; 2019():6480865. PubMed ID: 30895194
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive Evaluation of the m
Yu M; Liu X; Xu H; Shen S; Wang F; Chen D; Li G; Wang Z; Zuo Z; Zhao A
Front Immunol; 2022; 13():818120. PubMed ID: 35784363
[TBL] [Abstract][Full Text] [Related]
38. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing.
Malouf GG; Zhang J; Yuan Y; Compérat E; Rouprêt M; Cussenot O; Chen Y; Thompson EJ; Tannir NM; Weinstein JN; Valero V; Khayat D; Spano JP; Su X
Mol Oncol; 2015 Jan; 9(1):32-43. PubMed ID: 25126716
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma.
Sargent ER; Gomella LG; Belldegrun A; Linehan WM; Kasid A
J Urol; 1989 Nov; 142(5):1364-8. PubMed ID: 2810532
[TBL] [Abstract][Full Text] [Related]
40. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
